Bonjour , 

Je suis médecin généraliste en Belgique , actuellement nos instances officielles ne parlent pratiquement plus du COVID , à part le fait qu' elles nous demandent de ne faire des tests que chez les personnes à risques majeurs . Il n' y a plus de campagne de sensibilisation médiatique quant aux précautions à prendre et surtout plus un mot sur la vaccination . Il faut savoir que je suis pour la vaccination , non pas comme prévention de la maladie elle-même mais bien contre les complications éventuelles de celle-ci . J' encourage donc mes patients à y réfléchir . Hors actuellement j' arrive chez mes patients plus à risques à 5 à 6 mois de leur dernières injections, ce qui me semble un délais raisonnable pour leur proposer de "booster" . J' aimerais connaître un peu la politique de vos pays respectifs quant à la vaccination , les délais recommandés entre les différentes injections et certainement votre avis . Je précise que je ne désire pas un débat sur le vaccin en lui même mais bien l' avis des personnes qui sont convaincues de l' efficacité de celui-ci et de l' opportunité ou non de le maintenir . Je vous remercie de votre attention et vos éventuelles réponses . 

Dr P. Gosselin. 

Bon, je vais être plus clair, mon opinion sur la vaccination est faite , celle-ci n' est pa apparue par une illumination quelconque mais bien après consultations de différents articles scientifiques, l' expérience personnelle de soins de patients (en n'oubliant pas que la plupart des cas de COVID ont été traités en médecine générale , ce ne sont que les complications qui ont dû être hospitalisées ) , en consultant et questionnant mes confrères infectiologues, de médecines internes,.......et que sais-je encore . Cela pour dire que ma question n' a rien à voir avec  un débat sur vaccination ou pas , je pense qu' il y en a déjà eu assez et de toute façon ce sera dans bien des années que l' on pourra en tirer d' éventuelles conclusions . Donc ceux qui sont contre la vaccination ne sont pas concernés par ma question , ils ont fait un choix que je respecte , mais leur réponse sera  de ne pas vacciner s' ils suivent leurs convictions . 

Bivalent booster recipients had slightly higher protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and significantly higher protection against death than was observed for monovalent booster recipients or unvaccinated persons, especially among older adults, according to the US Centers for Disease Control and Prevention’s (CDC) latest Morbidity and Mortality Weekly Report.

A study published in the journal Vaccine evaluated the effects of a booster dose of BNT162b2 (Pfizer-BioNTech) vaccine on spike-binding antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron BA.2, BA.3, BA.4 and BA.5 subvariants in infection-naïve and previously-infected individuals

British Columbia is preparing for a fall rollout of an updated COVID-19 vaccine, tailored specifically to the Omicron variant. Provincial health officer Dr. Bonnie Henry emphasized that the new vaccine should be seen as an annual immunization similar to the flu shot, rather than just a booster dose. The recommendation from the National Advisory Committee on Immunization (NACI) suggests that Canadians should receive the updated vaccine if it has been six months since their last dose or COVID-19 infection. The aim is to provide protection against the strains circulating in Canada and globally, building upon the immunity gained from previous vaccinations. The province plans to make the vaccination process easy and convenient, and anyone who wants the vaccine will be offered it. With the anticipation of a potential fall surge of the virus, health officials are urging the public to stay informed and take advantage of this updated vaccine to help combat COVID-19 and ensure community protection...Read More

What are your thoughts?

News Medical

The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in more than 600 million confirmed cases and 6.5 million deaths worldwide.mRNA-based vaccines have emerged as a leading platform for COVID-19 protection and are extensively investigated in basic and clinical trials. SYS6006 (CSPC Pharmaceutical Group) is a newly investigational COVID-19 mRNA vaccine encoding a full-length S protein sequence of the prototype SARS-CoV-2 strain and incorporating the key mutations of main epidemic variants.

In March 2023, it has been authorized for emergent use in China by the national medicinal product agency (NMPA) of China. Yet, the data from clinical trials have not been published before. Moreover, the third dose of inactivated vaccine of COVID-19 has been proposed as the initial boosting regimen, and the second heterologous booster (the fourth dose of the vaccine) is worth investigating. By enrolling eligible healthy subjects and convalescent COVID-19 patients, researchers from Shanghai Xuhui Central Hospital have worked and unveiled the first clinical safety and efficacy profile of SYS6006.

These results demonstrated that a modified mRNA vaccine SYS6006 was safe and highly immunogenic as a heterologous booster in healthy Chinese adults. The strong enhancement of antibody titers after heterologous boosting is encouraging, along with the broad-spectrum neutralizing activity of these antibodies against variants of concern, such as Omicron BA.2 and BA.4/5. The titers in the SYS6006 group were higher than those in the convalescent patients. These findings suggest the flexible use of the mRNA vaccine as a booster regimen, which could accelerate the end of the pandemic...Read more

What are your thoughts on this study?

THURSDAY, June 15, 2023 (HealthDay News) -- An advisory panel to the U.S. Food and Drug Administration voted unanimously on Thursday to recommend that COVID-19 booster shots be updated for the fall to protect solely against one of the three XBB variants that have taken hold in the United States.

Those three XBB variants, which are all sublineages of the omicron variant, are XBB.1.5, XBB.1.16, and XBB.2.3, CNN reported. What will be dropped from the updated vaccines will be protection against the original strain of the virus because experts believe it could contribute to lower vaccine efficacy against newer strains.

"Your immune response likes to react to what it's seen before," David Ho, M.D., a professor of microbiology and immunology at Columbia University whose research was cited in FDA briefing documents, told CNN. "That's why we made the recommendation that if you want to broaden out your antibody responses, it's best to remove the ancestral spike in future vaccines."

Although the FDA will make the final decision on the updated vaccines, it typically follows the advice of its advisory panels.

While infections have declined across the United States, the virus could be a concern next winter, the FDA's vaccine chief Peter Marks, M.D., said as the daylong meeting began, the Associated Press reported. "We're concerned that we may have another wave of COVID-19 during a time when the virus has further evolved, immunity of the population has waned further, and we move indoors for wintertime," he told the panel.

A big question will be who should get the updated boosters, Paul Offit, M.D., a vaccine scientist at the Children's Hospital of Philadelphia and a member of the advisory committee, told CNN before Thursday's meeting. "What's the goal of the vaccine?" he asked. "If the goal of the vaccine is the stated goal, which is protection against severe disease, do you really need a yearly vaccine for otherwise healthy people less than 75? I mean, is this the flu model? Because I would argue it shouldn't be."

It is important to have evidence about whether protection from the COVID-19 vaccine against hospitalization and death is waning and, if so, in which groups, Offit added. In a presentation at the advisory panel meeting, the U.S. Centers for Disease Control and Prevention said there is evidence of waning protection from bivalent boosters against hospitalization, CNN reported.

COVID-19 boosters will likely be offered this fall, once they are redesigned by vaccine makers.

CNN Article

Associated Press Article

Copyright © 2020 HealthDay. All rights reserved.